Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US
Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence.
- Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence.
- The FDA granted Breakthrough Device designation to Synchron in August 2020 .
- We are thrilled to finally be launching a U.S. clinical trial this year, said Synchron CEO Thomas Oxley, MD, PhD.
- Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long term brain inflammation.